X
Search Filters
Format Format
Format Format
X
Sort by Item Count (A-Z)
Filter by Count
Journal Article (589) 589
Patent (310) 310
Publication (14) 14
Book / eBook (2) 2
Book Chapter (2) 2
Book Review (2) 2
Conference Proceeding (2) 2
Dissertation (2) 2
more...
Subjects Subjects
Subjects Subjects
X
Sort by Item Count (A-Z)
Filter by Count
humans (187) 187
index medicus (154) 154
female (140) 140
fixed constructions (140) 140
male (140) 140
middle aged (127) 127
aged (113) 113
earth drilling (98) 98
mining (98) 98
galleries (96) 96
large underground chambers (96) 96
performing operations (96) 96
shafts (96) 96
transporting (96) 96
tunnels (96) 96
oncology (94) 94
adult (74) 74
physics (68) 68
blasting (64) 64
heating (64) 64
lighting (64) 64
mechanical engineering (64) 64
weapons (64) 64
treatment outcome (62) 62
chemotherapy (56) 56
cancer (54) 54
general tagging of cross-sectional technologies spanning over several sections of the ipc (52) 52
general tagging of new technological developments (52) 52
technical subjects covered by former uspc cross-reference art collections [xracs] and digests (52) 52
antineoplastic combined chemotherapy protocols - therapeutic use (50) 50
engineering elements and units (46) 46
general measures for producing and maintaining effectivefunctioning of machines or installations (46) 46
land vehicles for travelling otherwise than on rails (46) 46
motor vehicles (46) 46
thermal insulation in general (46) 46
trailers (46) 46
cardiac & cardiovascular systems (45) 45
technical subjects covered by former us classification (43) 43
technical subjects covered by former uspc (43) 43
colorectal cancer (42) 42
gearing (41) 41
research (41) 41
catheter ablation (39) 39
atrial fibrillation (37) 37
foundations (37) 37
hydraulic engineering (37) 37
soil shifting (37) 37
dredging (36) 36
metastasis (36) 36
soil-shifting (36) 36
analysis (34) 34
japan (34) 34
aged, 80 and over (33) 33
colorectal neoplasms - drug therapy (33) 33
medicine & public health (33) 33
care and treatment (31) 31
vehicles in general (31) 31
camptothecin - analogs & derivatives (30) 30
animals (29) 29
colorectal neoplasms - pathology (29) 29
gastroenterology & hepatology (29) 29
clinical trials (28) 28
antineoplastic combined chemotherapy protocols - adverse effects (27) 27
camptothecin - administration & dosage (27) 27
optics (27) 27
drug combinations (26) 26
machine tools (26) 26
metal-working not otherwise provided for (26) 26
expression (25) 25
irinotecan (25) 25
chemistry (24) 24
electricity (24) 24
stomach cancer (24) 24
metallurgy (23) 23
prognosis (23) 23
survival (23) 23
tegafur - administration & dosage (23) 23
therapy (23) 23
trial (23) 23
ablation (22) 22
controlling (22) 22
disease-free survival (22) 22
fluorouracil (22) 22
hand tools (22) 22
manipulators (22) 22
optical elements, systems, or apparatus (22) 22
oxonic acid - administration & dosage (22) 22
portable power-driven tools (22) 22
regulating (22) 22
combined operations (21) 21
original (21) 21
other working of metal (21) 21
retrospective studies (21) 21
universal machine tools (21) 21
atrial fibrillation - surgery (20) 20
bevacizumab (20) 20
catheter ablation - methods (20) 20
chambers provided with manipulation devices (20) 20
oncology, experimental (20) 20
pharmacology & pharmacy (20) 20
more...
Language Language
Language Language
X
Sort by Item Count (A-Z)
Filter by Count
English (850) 850
Japanese (62) 62
French (23) 23
German (15) 15
Chinese (14) 14
Korean (3) 3
Italian (2) 2
more...
Publication Date Publication Date
Click on a bar to filter by decade
Slide to change publication date range


Lancet Oncology, The, ISSN 1470-2045, 2014, Volume 15, Issue 11, pp. 1224 - 1235
Summary Background VEGFR-2 has a role in gastric cancer pathogenesis and progression. We assessed whether ramucirumab, a monoclonal antibody VEGFR-2... 
Hematology, Oncology and Palliative Medicine | SUPPORTIVE CARE | ONCOLOGY | BEVACIZUMAB | CLINICAL-TRIALS | GROWTH | 2ND-LINE CHEMOTHERAPY | OPEN-LABEL | 1ST-LINE THERAPY | COMBINATION | CANCER | III TRIAL | Confidence Intervals | Adenocarcinoma - pathology | Prognosis | Humans | Middle Aged | Antibodies, Monoclonal - adverse effects | Antineoplastic Combined Chemotherapy Protocols - adverse effects | Male | Stomach Neoplasms - pathology | Esophageal Neoplasms - pathology | Dose-Response Relationship, Drug | Esophageal Neoplasms - mortality | Adult | Female | Remission Induction - methods | Paclitaxel - administration & dosage | Double-Blind Method | Drug Administration Schedule | Kaplan-Meier Estimate | Proportional Hazards Models | Esophagogastric Junction - pathology | Paclitaxel - adverse effects | Treatment Outcome | Stomach Neoplasms - drug therapy | Adenocarcinoma - drug therapy | Disease-Free Survival | Maximum Tolerated Dose | Antibodies, Monoclonal - administration & dosage | Antineoplastic Combined Chemotherapy Protocols - therapeutic use | Survival Analysis | Aged | Esophageal Neoplasms - drug therapy | Stomach Neoplasms - mortality | Adenocarcinoma - mortality | Antimitotic agents | Care and treatment | Hospitals | Clinical trials | Monoclonal antibodies | Product development | Antineoplastic agents | Vascular endothelial growth factor | Esophageal cancer
Journal Article
Journal Article
Lancet Oncology, The, ISSN 1470-2045, 2013, Volume 14, Issue 13, pp. 1278 - 1286
Journal Article
The New England Journal of Medicine, ISSN 0028-4793, 05/2015, Volume 372, Issue 20, pp. 1909 - 1919
Journal Article
Lancet Oncology, The, ISSN 1470-2045, 2010, Volume 11, Issue 9, pp. 853 - 860
Summary Background Fluorouracil and folinic acid with either oxaliplatin (FOLFOX) or irinotecan (FOLFIRI) are widely used as first-line or second-line... 
Hematology, Oncology and Palliative Medicine | TRIAL | CAPECITABINE | 1ST-LINE TREATMENT | INFUSIONAL FLUOROURACIL/LEUCOVORIN | THERAPY | ONCOLOGY | 5-FLUOROURACIL/FOLINIC ACID | FLUOROPYRIMIDINES | OXALIPLATIN | III NONINFERIORITY | FAILURE | Prodrugs - administration & dosage | Leucovorin - administration & dosage | Antineoplastic Combined Chemotherapy Protocols - administration & dosage | Humans | Middle Aged | Antineoplastic Combined Chemotherapy Protocols - adverse effects | Male | Organoplatinum Compounds - administration & dosage | Fluorouracil - administration & dosage | Leucovorin - adverse effects | Fluorouracil - adverse effects | Colorectal Neoplasms - drug therapy | Adult | Camptothecin - administration & dosage | Female | Camptothecin - analogs & derivatives | Colorectal Neoplasms - mortality | Camptothecin - adverse effects | Fluorouracil - analogs & derivatives | Tegafur - adverse effects | Kaplan-Meier Estimate | Oxonic Acid - administration & dosage | Adenocarcinoma - drug therapy | Oxonic Acid - adverse effects | Disease-Free Survival | Prodrugs - adverse effects | Antineoplastic Combined Chemotherapy Protocols - therapeutic use | Tegafur - administration & dosage | Aged | Drug Combinations | Adenocarcinoma - mortality | Medical colleges | Chemotherapy | Oncology, Experimental | Colorectal cancer | Leucovorin | Research | Metastasis | Cancer | Fluorouracil | Analysis
Journal Article
International Journal of Radiation Oncology, Biology, Physics, ISSN 0360-3016, 2011, Volume 81, Issue 3, pp. 684 - 690
Purpose In this Phase II study, we evaluated the efficacy and toxicity of chemoradiotherapy (CRT) with cisplatin (CDDP) and 5-fluorouracil (5-FU) for Stage... 
Radiology | Hematology, Oncology and Palliative Medicine | Esophageal squamous cell carcinoma | Long-term toxicity | Salvage surgery | Chemoradiotherapy | SURGERY | SURVIVAL | THORACIC ESOPHAGUS | CANCER | CHEMOTHERAPY | SALVAGE ESOPHAGECTOMY | RADIATION-THERAPY | ONCOLOGY | CHEMORADIATION | RADIOTHERAPY | DEFINITIVE CHEMORADIOTHERAPY | RADIOLOGY, NUCLEAR MEDICINE & MEDICAL IMAGING | Chemoradiotherapy - adverse effects | Age Factors | Carcinoma, Squamous Cell - pathology | Humans | Middle Aged | Antineoplastic Combined Chemotherapy Protocols - adverse effects | Male | Cisplatin - administration & dosage | Esophageal Neoplasms - pathology | Carcinoma, Squamous Cell - mortality | Fluorouracil - administration & dosage | Esophageal Neoplasms - mortality | Adult | Female | Surveys and Questionnaires | Esophageal Neoplasms - therapy | Radiotherapy Dosage | Chemoradiotherapy - methods | Drug Administration Schedule | Carcinoma, Squamous Cell - therapy | Survival Rate | Remission Induction | Antineoplastic Combined Chemotherapy Protocols - therapeutic use | Aged | Health Status | Neoplasm Staging | Salvage Therapy - methods | Preoperative Care - methods | Medical colleges | Chemotherapy | Squamous cell carcinoma | Information services | Clinical trials | Esophageal cancer | Information services industry | Cisplatin | Cancer | Fluorouracil | Index Medicus | ESOPHAGUS | DIGESTIVE SYSTEM | COMPLEXES | HETEROCYCLIC COMPOUNDS | DEATH | INFUSION | MEDICINE | AZINES | ANTIMETABOLITES | FLUOROURACILS | IRRADIATION | ORGANIC HALOGEN COMPOUNDS | HYDROXY COMPOUNDS | THERAPY | DRUGS | RADIOLOGY AND NUCLEAR MEDICINE | PNEUMONITIS | ORGANIC NITROGEN COMPOUNDS | COMBINED THERAPY | RADIOLOGY | URACILS | NEOPLASMS | ORGANIC COMPOUNDS | ORGANIC FLUORINE COMPOUNDS | INTAKE | PYRIMIDINES | TOXICITY | SYMPTOMS | TRANSITION ELEMENT COMPLEXES | PLATINUM COMPLEXES | NUCLEAR MEDICINE | ORGANS | SURVIVAL TIME | DISEASES | CARCINOMAS | NAUSEA | BODY
Journal Article
Gan to kagaku ryoho. Cancer & chemotherapy, ISSN 0385-0684, 11/2016, Volume 43, Issue 11, p. 1357
Journal Article
Japanese Journal of Cancer and Chemotherapy, ISSN 0385-0684, 11/2016, Volume 43, Issue 11, pp. 1357 - 1360
Journal Article
Cancer Science, ISSN 1347-9032, 07/2015, Volume 106, Issue 7, pp. 891 - 895
Journal Article
Lancet Oncology, The, ISSN 1470-2045, 2016, Volume 17, Issue 1, pp. 99 - 108
Journal Article
Gastric Cancer, ISSN 1436-3291, 10/2015, Volume 18, Issue 4, pp. 824 - 832
This multicenter, randomized phase II trial was conducted to compare the efficacy and safety of nimotuzumab plus irinotecan (N-IRI) versus irinotecan alone... 
Irinotecan | Anti-EGFR | Medicine & Public Health | Gastroenterology | Second-line therapy | Abdominal Surgery | Oncology | Cancer Research | Surgical Oncology | Advanced gastric cancer | Nimotuzumab | ADVANCED ESOPHAGOGASTRIC CANCER | MONOCLONAL-ANTIBODY H-R3 | CHEMOTHERAPY PLUS | CELL LUNG-CANCER | CAPECITABINE | GROWTH-FACTOR RECEPTOR | SUPPORTIVE CARE | CISPLATIN | ONCOLOGY | EGFR ANTIBODY | 1ST-LINE THERAPY | GASTROENTEROLOGY & HEPATOLOGY | Immunohistochemistry | Receptor, Epidermal Growth Factor - genetics | Humans | Middle Aged | Neoplasm Recurrence, Local - drug therapy | Male | Neoplasm Recurrence, Local - mortality | Antibodies, Monoclonal, Humanized - administration & dosage | DNA Mutational Analysis | Polymerase Chain Reaction | Adult | Camptothecin - administration & dosage | Female | Adenocarcinoma - genetics | Camptothecin - analogs & derivatives | Genes, ras - genetics | Stomach Neoplasms - genetics | Antibodies, Monoclonal, Humanized - adverse effects | Camptothecin - adverse effects | Receptor, Epidermal Growth Factor - biosynthesis | Receptor, ErbB-2 - biosynthesis | Kaplan-Meier Estimate | In Situ Hybridization, Fluorescence | Treatment Outcome | Stomach Neoplasms - drug therapy | Adenocarcinoma - drug therapy | Disease-Free Survival | Antineoplastic Combined Chemotherapy Protocols - therapeutic use | Neoplasm Recurrence, Local - genetics | Aged | Stomach Neoplasms - mortality | Salvage Therapy - methods | Adenocarcinoma - mortality | Antimitotic agents | Care and treatment | Cancer patients | Clinical trials | Product development | Antineoplastic agents | Stomach cancer | Cancer | Original
Journal Article
Gastric Cancer, ISSN 1436-3291, 7/2016, Volume 19, Issue 3, pp. 927 - 938
Journal Article